Mesoblast Raises A$75 Million
Filed with ASX · · 2 pages · English
Story so far
Earlier from Mesoblast
- Grunenthal and MSB Enter Strategic Partnership for Back Pain
- Mesoblast Reports on Annual Results
- FDA Guidance on Clinical Pathway for LVAD Market Application
- Appendix 4C - Quarterly, Strong Commercialization Revenues
- Circulation Research Highlights MSB Heart Failure Therapy
Later from Mesoblast
- MSB and Lonza Enter GVHD Commercial Manufacturing Agreement
- MSB Provides Q1 Financial Results and Operational Highlights
- CHF P3 Trial Accrues Sufficient Primary Endpoint Events
- CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)
- DMC Completes Final Review of Phase 3 Heart Failure Trial
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast